Menlo Therapeutics Inc
4085 Campbell Avenue
About Menlo Therapeutics IncMenlo Therapeutics Inc. (formerly Tigercat Pharma, Inc.) is a clinical stage pharmaceutical company focused on the development and commercialization of serlopitant for the treatment of severe, chronic pruritus (itch). Serlopitant (VPD-737) is a potent oral NK1 receptor antagonist that Menlo Therapeutics exclusively licensed from Merck in 2012. Menlo Therapeutics investors include Vivo Capital, F-Prime Capital, Presidio Partners and Remeditex Ventures.
CEO: Steven Basta
CMO: Paul Kwon
19 articles with Menlo Therapeutics Inc
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
Thornton Law Firm LLP is investigating a potential lawsuit on behalf of purchasers of the securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) pursuant or traceable to the registration statement and prospectus issued in connection with Menlo's January 2018 initial public offering ("IPO").
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Menlo Therapeutics Inc. (MNLO)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc.
Menlo Therapeutics' stock dropped 55 percent in premarket trading after announcing its serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.
Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Menlo’s common stock is listed on The NASDAQ Global Select Market under the ticker symbol “MNLO.”
The offering is expected to close on January 29, 2018, subject to customary closing conditions.
Menlo Therapeutics filed on Thursday with the SEC to raise up to $98M in an IPO.
The PSORIXA study, MTI-109, is a multi-center, randomized, placebo-controlled study evaluating the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus associated with psoriasis.
Menlo Therapeutics Initiates Enrollment in Phase II Clinical Trial with Serlopitant for Refractory Chronic Cough
Menlo Therapeutics has initiated enrollment in a 170-subject Phase II trial evaluating serlopitant as a treatment for refractory chronic cough.
Menlo Therapeutics is developing a neurokinin 1 (NK1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and for the treatment of refractory chronic cough.
Menlo Therapeutics Release: Serlopitant Pruritus Reduction Results From Two Phase II Studies Presented At The 26th European Academy Of Dermatology And Venereology
Menlo Therapeutics Announces Successful Pruritus Reduction Results From Phase 2 Serlopitant Trial (TCP-102) In 127 Subjects With Prurigo Nodularis
Menlo Therapeutics Starts Enrollment In Two Phase 2 Studies For Pruritus Associated With Atopic Dermatitis And Pruritus Following Burn Injury
Menlo Therapeutics Recruits Experienced Management Team And Board Leadership To Accelerate Development Of Serlopitant For Treatment Of Pruritus
Menlo Therapeutics Signs Exclusive License Agreement With Japan Tobacco And Torii Pharmaceuticals For Development And Commercialization Of NK-1 Receptor Antagonist In Japan